The numbers
Medvi, an emerging player in the artificial intelligence sector, is projected to reach $1.8 billion in revenue by 2026. Founded by Matthew Gallagher in September 2024 with just $20,000 in start-up capital, the company has rapidly scaled its operations, achieving $401 million in sales during its first year.
By the end of 2025, Medvi had reached approximately 250,000 clients, and it is expected to expand its reach to over 500,000 patients in 2026. The company operates with a remarkably lean structure, employing only two permanent staff members: Gallagher and his brother, Elliot.
Medvi has leveraged over a dozen AI tools to streamline various business functions, illustrating how technology can facilitate ultra-lean, hyper-scalable companies. Gallagher’s innovative approach has drawn attention to the potential of AI in transforming traditional business models.
However, Medvi’s rapid ascent has not been without controversy. The FDA issued a warning letter to the company regarding inaccurate claims about its products, cautioning that failure to correct these violations could lead to seizures or legal bans. Additionally, Medvi’s marketing strategies have come under scrutiny for utilizing AI-generated personas with fictional medical titles.
Several lawsuits have been filed against Medvi for consumer fraud and inaccurate scientific claims, raising concerns about the ethical implications of its business practices. Details remain unconfirmed regarding the nature of these lawsuits and the external partners used for medical services and drug distribution.
As Medvi continues to grow, observers are closely monitoring how the company addresses these challenges while striving to meet its ambitious revenue targets. Itamar Friedman, a commentator on AI applications, noted, “AI is not enough when you’re talking about real-world software quality and code governance,” emphasizing the need for robust governance in tech-driven companies.
Despite the hurdles, Gallagher’s vision for Medvi showcases the transformative potential of AI in the healthcare sector. The company’s trajectory reflects a broader trend of startups harnessing technology to disrupt traditional industries, though the path forward remains fraught with regulatory and legal challenges.